US OptionsDetailed Quotes
GPCR241115P42500
- 3.70
- +0.20+5.71%
15min DelayClose Nov 4 16:00 ET
3.70High3.70Low
3.70Open3.50Pre Close5 Volume12 Open Interest42.50Strike Price1.85KTurnover92.67%IV2.37%PremiumNov 15, 2024Expiry Date2.76Intrinsic Value100Multiplier11DDays to Expiry0.94Extrinsic Value100Contract SizeAmericanOptions Type-0.6299Delta0.0594Gamma9.46Leverage Ratio-0.1090Theta-0.0079Rho-5.96Eff Leverage0.0260Vega
Structure Therapeutics Stock Discussion
go go fly my loving stock
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
No comment yet